The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
Open accessAbstract
BACKGROUND: In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis and a high risk of death. The FDA required a study to evaluate the efficacy of DrotAA for adults who had severe sepsis and a low risk of death. METHODS: We randomly assigned adult patients with severe sepsis and a low risk of death (defined by an Acute Physiology and Chronic Health Evaluation [APACHE II] score <25 or single-organ failure) to receive an intravenous infusion of placebo or DrotAA (24 microg per kilogram of body weight per hour) for 96 hours in a double-blind, placebo-controlled, multicenter trial. The prospectively defined primary end point was death from any cause and was assessed 28 days after the start of the infusion. In-hospital mortality within 90 days after the start of the infusion was measured, and safety information was collected. RESULTS: Enrollment in the trial was terminated early because of a low likelihood of meeting the prospectively defined objective of demonstrating a significant reduction in the 28-day mortality rate with the use of DrotAA. The study enrolled 2640 patients and collected data on 2613 (1297 in the placebo group and 1316 in the DrotAA group) at the 28-day follow-up. There were no statistically significant differences between the placebo group and the DrotAA group in 28-day mortality (17.0 percent in the placebo group vs. 18.5 percent in the DrotAA group; P=0.34; relative risk, 1.08; 95 percent confidence interval, 0.92 to 1.28) or in in-hospital mortality (20.5 percent vs. 20.6 percent; P=0.98; relative risk, 1.00; 95 percent confidence interval, 0.86 to 1.16). The rate of serious bleeding was greater in the DrotAA group than in the placebo group during both the infusion (2.4 percent vs. 1.2 percent, P=0.02) and the 28-day study period (3.9 percent vs. 2.2 percent, P=0.01). CONCLUSIONS: The absence of a beneficial treatment effect, coupled with an increased incidence of serious bleeding complications, indicates that DrotAA should not be used in patients with severe sepsis who are at low risk for death, such as those with single-organ failure or an APACHE II score less than 25.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., & Pinsky, M. R. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107000-00002 · Cited by 8,503
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Bernard, G. R., Vincent, J.-L., Laterre, P.-F., LaRosa, S. P., Dhainaut, J.-F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441001 · Cited by 6,132
Self-citationUse of intensive care at the end of life in the United States: An epidemiologic study*
Angus, D. C., Barnato, A. E., Linde-Zwirble, W. T., Weissfeld, L. A., Watson, R. S., Rickert, T., & Rubenfeld, G. D. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000114816.62331.08 · Cited by 1,155
Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study
Alberti, C., Brun-Buisson, C., Burchardi, H., Martin, C., Goodman, S., Artigas, A., Sicignano, A., Palazzo, M., Moreno, R., Boulmé, R., et al. (2002) · Intensive Care Medicine · doi:10.1007/s00134-001-1143-z · Cited by 979
Brun-Buisson, C. (1995) · JAMA · doi:10.1001/jama.1995.03530120060042 · Cited by 772
Epidemiology of Sepsis Syndrome in 8 Academic Medical Centers
Sands, K. E. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550030074038 · Cited by 663
(2004) · Intensive Care Medicine · doi:10.1007/s00134-003-2121-4 · Cited by 638
Padkin, A., Goldfrad, C., Brady, A. R., Young, D., Black, N., & Rowan, K. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000085141.75513.2b · Cited by 454
Cited by
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
Seymour, C. W., Kennedy, J. N., Wang, S., Chang, C.-C. H., Elliott, C. F., Xu, Z., Berry, S., Clermont, G., Cooper, G., Gomez, H., et al. (2019) · JAMA · doi:10.1001/jama.2019.5791 · Cited by 1,567
Kaukonen, K.-M., Bailey, M., Suzuki, S., Pilcher, D., & Bellomo, R. (2014) · JAMA · doi:10.1001/jama.2014.2637 · Cited by 1,459
Drotrecogin Alfa (Activated) in Adults with Septic Shock
Ranieri, V. M., Thompson, B. T., Barie, P. S., Dhainaut, J.-F., Douglas, I. S., Finfer, S., Gårdlund, B., Marshall, J. C., Rhodes, A., Artigas, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202290 · Cited by 1,309
Self-citationGuidelines for the diagnosis and management of disseminated intravascular coagulation
Levi, M., Toh, C. H., Thachil, J., & Watson, H. G. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07600.x · Cited by 1,119
Russell, J. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra043632 · Cited by 1,048
Adjunctive glucocorticoid therapy in patients with septic shock.
Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., Harward, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705835 · Cited by 1,037
Levi, M., & van der Poll, T. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181c98d21 · Cited by 984
Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis
Brouwer, M. C., Tunkel, A. R., & van de Beek, D. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00070-09 · Cited by 930
The Pathogenesis of Sepsis and Potential Therapeutic Targets
Huang, M., Cai, S., & Su, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215376 · Cited by 776
The cytoprotective protein C pathway
Mosnier, L. O., Zlokovic, B. V., & Griffin, J. H. (2007) · Blood · doi:10.1182/blood-2006-09-003004 · Cited by 754
Variation in critical care services across North America and Western Europe*
Wunsch, H., Angus, D. C., Harrison, D. A., Collange, O., Fowler, R., Hoste, E. A. J., de Keizer, N. F., Kersten, A., Linde-Zwirble, W. T., Sandiumenge, A., et al. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318186aec8 · Cited by 624
Host–pathogen interactions in sepsis
van der Poll, T., & Opal, S. M. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70265-7 · Cited by 553
Stearns-Kurosawa, D. J., Osuchowski, M. F., Valentine, C., Kurosawa, S., & Remick, D. G. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130327 · Cited by 549
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
Kent, D. M., Rothwell, P. M., Ioannidis, J. P., Altman, D. G., & Hayward, R. A. (2010) · Trials · doi:10.1186/1745-6215-11-85 · Cited by 504
Remick, D. G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060872 · Cited by 501
Nadel, S., Goldstein, B., Williams, M. D., Dalton, H., Peters, M., Macias, W. L., Abd-Allah, S. A., Levy, H., Angle, R., Wang, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60411-5 · Cited by 501
Self-citationPersonalized evidence based medicine: predictive approaches to heterogeneous treatment effects
Kent, D. M., Steyerberg, E., & van Klaveren, D. (2018) · BMJ · doi:10.1136/bmj.k4245 · Cited by 479
Septic shock attributed to Candida infection: Importance of empiric therapy and source control.
Kollef, M., Micek, S., Hampton, N., Doherty, J. A., & Kumar, A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis305 · Cited by 477
Wada, H., Thachil, J., Di Nisio, M., Mathew, P., Kurosawa, S., Gando, S., Kim, H. K., Nielsen, J. D., Dempfle, C.-E., Levi, M., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12155 · Cited by 454
Sepsis: Multiple Abnormalities, Heterogeneous Responses, and Evolving Understanding
Iskander, K. N., Osuchowski, M. F., Stearns-Kurosawa, D. J., Kurosawa, S., Stepien, D., Valentine, C., & Remick, D. G. (2013) · Physiological Reviews · doi:10.1152/physrev.00037.2012 · Cited by 453
Gustot, T., Durand, F., Lebrec, D., Vincent, J., & Moreau, R. (2009) · Hepatology · doi:10.1002/hep.23264 · Cited by 447
Nakahira, K., Kyung, S.-Y., Rogers, A. J., Gazourian, L., Youn, S., Massaro, A. F., Quintana, C., Osorio, J. C., Wang, Z., Zhao, Y., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001577 · Cited by 445
Effectiveness of treatments for severe sepsis: A prospective, multicenter, observational study.
Ferrer, R., Artigas, A., Suarez, D., Palencia, E., Levy, M. M., Arenzana, A., Pérez, X. L., & Sirvent, J.-M. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200812-1912oc · Cited by 433
Fink, M. P. (2014) · Virulence · doi:10.4161/viru.26083 · Cited by 391
Castellanos-Ortega, Á., Suberviola, B., García-Astudillo, L. A., Holanda, M. S., Ortiz, F., Llorca, J., & Delgado-Rodríguez, M. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d455b6 · Cited by 363
Nguyen, H. B., Rivers, E. P., Abrahamian, F. M., Moran, G. J., Abraham, E., Trzeciak, S., Huang, D. T., Osborn, T., Stevens, D., & Talan, D. A. (2006) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2006.02.015 · Cited by 356
Self-citationSignaling pathways and intervention therapies in sepsis
Zhang, Y.-Y., & Ning, B.-T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00816-9 · Cited by 349
The role of infection and comorbidity: Factors that influence disparities in sepsis
Esper, A. M., Moss, M., Lewis, C. A., Nisbet, R., Mannino, D. M., & Martin, G. S. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000239114.50519.0e · Cited by 336
Wada, H., Matsumoto, T., & Yamashita, Y. (2014) · Journal of Intensive Care · doi:10.1186/2052-0492-2-15 · Cited by 325
Disseminated intravascular coagulation
Levi, M. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000281468.94108.4b · Cited by 324
The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer?
Boomer, J. S., Green, J. M., & Hotchkiss, R. S. (2014) · Virulence · doi:10.4161/viru.26516 · Cited by 317
Sepsis-Associated Myocardial Dysfunction
Maeder, M., Fehr, T., Rickli, H., & Ammann, P. (2006) · Chest · doi:10.1378/chest.129.5.1349 · Cited by 310
Sepsis: Inflammation Is a Necessary Evil
Nedeva, C., Menassa, J., & Puthalakath, H. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00108 · Cited by 301
Early Goal-Directed Therapy in Severe Sepsis and Septic Shock Revisited
Otero, R. M., Nguyen, H. B., Huang, D. T., Gaieski, D. F., Goyal, M., Gunnerson, K. J., Trzeciak, S., Sherwin, R., Holthaus, C. V., Osborn, T., et al. (2006) · Chest · doi:10.1378/chest.130.5.1579 · Cited by 296
Schuetz, P., Birkhahn, R., Sherwin, R., Jones, A. E., Singer, A., Kline, J. A., Runyon, M. S., Self, W. H., Courtney, D. M., Nowak, R. M., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002321 · Cited by 296
Clinical review: The liver in sepsis
Nesseler, N., Launey, Y., Aninat, C., Morel, F., Mallédant, Y., & Seguin, P. (2012) · Critical Care · doi:10.1186/cc11381 · Cited by 293
Bundled care for septic shock: An analysis of clinical trials*
Barochia, A. V., Cui, X., Vitberg, D., Suffredini, A. F., OʼGrady, N. P., Banks, S. M., Minneci, P., Kern, S. J., Danner, R. L., Natanson, C., et al. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181cb0ddf · Cited by 279
Weitz, J. I., Hirsh, J., & Samama, M. M. (2008) · Chest · doi:10.1378/chest.08-0673 · Cited by 262
Sepsis and Septic Shock: A History
Funk, D. J., Parrillo, J. E., & Kumar, A. (2009) · Critical Care Clinics · doi:10.1016/j.ccc.2008.12.003 · Cited by 252
Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies
Barochia, A., Solomon, S., Cui, X., Natanson, C., & Eichacker, P. Q. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.558190 · Cited by 169
Problems of stopping trials early
Guyatt, G. H., Briel, M., Glasziou, P., Bassler, D., & Montori, V. M. (2012) · BMJ · doi:10.1136/bmj.e3863 · Cited by 115
Reduction in Mortality Associated with Statin Therapy in Patients with Severe Sepsis
Dobesh, P. P., Klepser, D. G., McGuire, T. R., Morgan, C. W., & Olsen, K. M. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.6.621 · Cited by 88
Bradford, M. A., Lindenauer, P. K., Wiener, R. S., & Walkey, A. J. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000403 · Cited by 43
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Critical Care Medicine · doi:10.1097/01.ccm.0000298158.12101.41 · Cited by 9
Metadata
- Authors
- Abraham, E., Laterre, P.-F., Garg, R., Levy, H., Talwar, D., Trzaskoma, B. L., François, B., Guy, J. S., Brückmann, M., Rea-Neto, Á., Rossaint, R., Perrotin, D., Sablotzki, A., Arkins, N., Utterback, B. G., & Macias, W. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-09-29
- Volume
- 353
- Issue
- 13
- Pages
- 1332-1341
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2154611259
- Cited by
- 890
- References
- 19
- FWCI
- 68.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.